Yesterday’s Annual General Meeting of Medicon Hellas saw some unexpected developments, during which shareholders approved all items on the agenda, with the main change being the increase in the dividend for the 2025 fiscal year.
While management’s initial proposal called for a distribution of 0.13 euros per share, following discussion at the General Meeting, it was decided to pay a dividend of 0.15 euros per share, gross. The total amount of the distribution is 662,942.40 euros, and after a 5% tax withholding, the net amount is 0.1425 euros per share.
The ex-dividend date has been set for Monday, July 13, 2026; shareholders registered with the Central Securities Depository (CSD) on Tuesday, July 14, 2026, will be eligible to receive the dividend, while payment will begin on Friday, July 17, 2026, through Euronext Athens and the participants in the Central Securities Depository (CSD).
Items Approved
At the General Meeting, the following were approved, among other items: the annual financial statements for fiscal year 2025, the appropriation of profits, the overall management of the Board of Directors, the compensation report, the remuneration of Board members, and the election of an auditing firm for the 2026 fiscal year. AUDITASK Certified Public Accountants, Auditors, and Business Consultants S.A., operating under the trade name JPA Audit Greece, was selected to conduct the regular audit of the financial statements.
A new seven-member Board of Directors was also elected for a six-year term. Following its formation, Spyridon Dimotsantos was appointed Chairman and CEO, while Georgios Dimotsantos was appointed Deputy CEO.
Vasileios Loumiotis, Efstratios Tserkezos, and Dimitrios Kapetanakis were elected to the new Audit Committee, while a Compensation and Nominating Committee is also being formed, with Dimitrios Kapetanakis, Efstratios Tserkezos, and Spyridoula Ktisti as its members.
The Plot of Land and Production
Of particular interest was the management’s mention of plans to purchase an 8.5-stremma plot of land adjacent to the company’s facilities in Gerakas. This is a site that is currently leased and used for Medicon’s logistics needs.
According to Chairman and CEO Spyridon Dimotsantos, once the agreement is finalized, the company plans to relocate the logistics operations currently housed in another of its buildings to that site. This will free up space for the creation of a second production facility, which will support existing production operations.
This move is part of a broader plan to strengthen the company’s infrastructure at a time when Medicon is seeking to further expand its presence in both diagnostics and new product and service categories.
Performance in 2025 and Forecasts for 2026
Despite a slight decline in sales, Medicon closed out 2025 with significantly improved profitability at the group level. Sales, after deducting rebates and clawbacks, stood at 17.954 million euros, down from 18.375 million euros in 2024, marking a 2.29% decrease.
However, the decline in revenue did not affect the bottom line, as EBITDA increased by 10.64%, to 3.773 million euros, while the rise in net profits was even stronger, increasing by 32.60% to 1.769 million euros.
For 2026, according to statements made at the General Meeting, the first half of the year is tracking close to the levels of the corresponding period last year. Diagnostics are showing growth in the range of 2%–3%, while the significant reduction in the clawback—which reached 12% in 2025—is expected to support profitability.
Management also mentioned the company’s entry into the microbiology sector, with tests related to antimicrobial resistance that will indicate which antibiotics a patient is resistant to.
Finally, regarding the source of revenue, exports account for approximately 20%, while the majority of revenue comes from public hospitals. In contrast, the share of small private patients remains limited at present.
Management, however, stated that Medicon intends to refocus its attention on this segment, seeing opportunities for a resurgence in a market where it previously had a stronger presence.